Table 4 Multivariable analyses of PFS and OS including IMDC risk group in each treatment arm by baseline biomarker level dichotomized at the median

HGF

1.57 (1.14, 2.16)*

1.39 (1.05, 1.84)*

0.53

2.28 (1.55, 3.35)*

1.57 (1.16, 2.13)*

0.16

MET

0.96 (0.71, 1.29)

1.11 (0.84, 1.47)

0.57

1.24 (0.88, 1.74)

1.33 (0.98, 1.8)

0.80

GAS6

1.29 (0.96, 1.74)

1.05 (0.80, 1.39)

0.35

1.83 (1.28, 2.6)*

1.37 (1.01, 1.86)*

0.20

AXL

1.39 (1.03, 1.88)*

0.87 (0.65, 1.15)

0.013*

1.40 (0.99, 1.98)

0.98 (0.72, 1.32)

0.14

VEGF

1.41 (1.03, 1.94)*

1.07 (0.81, 1.42)

0.16

1.72 (1.19, 2.49)*

1.34 (0.98, 1.82)

0.29

IL-8

1.03 (0.76, 1.40)

1.33 (1.01, 1.76)*

0.24

1.77 (1.25, 2.50)*

1.67 (1.23, 2.27)*

0.76